Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Summary: Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we d...

Full description

Bibliographic Details
Main Authors: Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey E. Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124719306874

Similar Items

Similar Items